CA-VERIMATRIX
Regulatory News:
Verimatrix, (Euronext Paris: VMX, FR0010291245), a global leader in powering the modern connected world with people-centered security, today announced its exciting plans for IBC 2024 taking place from September 13-17 in Amsterdam. Verimatrix’s IBC booth 1.C65 is set to become "Broadcast Beach," a vibrant, surf and sand-themed experience designed to transport attendees to the sunny shores of San Diego (home of Verimatrix’s U.S. office), while showcasing the company’s robust suite of security solutions, including its latest anti-piracy solution, Counterspy.
Counterspy, a new product in the Verimatrix Streamkeeper family, is a groundbreaking solution designed to tackle the escalating threat of digital video piracy in bold new ways. It offers unparalleled protection with a focus on tangible revenue-saving benefits for customers. IBC attendees will be able to experience a live demonstation that showcases how Counterspy customers can:
- Reduce Video Piracy: Counterspy provides a formidable defense against unauthorized access, significantly cutting down on piracy incidents and securing content across platforms.
- Protect Media Apps: With its advanced app protection and telemetry features, Counterspy shields media apps from reverse engineering, man-in-the-middle attacks, and other malicious activities, ensuring that only legitimate users can access content – and providing customers with a way to monitor and respond to piracy threats in real-time.
- Unlock Access to More Premium Content: By safeguarding content with Counterspy, operators can confidently expand their premium content offerings, meeting studio security requirements.
- Reduce CDN Costs: Counterspy directly addresses the issue of CDN leeching, enabling operators to cut CDN costs dramatically (one Verimatrix customer saw their CDN expenses drop by 50% after implementing Counterspy)
- Boost Paid Subscribers: By enhancing content security and reducing piracy, Counterspy helps customers maintain a trustworthy service vs. pirate services, which in turn helps drive subscriber growth and revenue.
The Verimatrix Broadcast Beach-themed booth at IBC 2024 will feature:
- Surfside Check-In: The first stop in the serene beachfront oasis where attendees can check in with a host and grab some wave-breaking Verimatrix swag.
- Counterspy Cove: Grab a seat at one of the high-back deck tables and interact with a live demo for Verimatrix Counterspy, the ultimate in video security defense, seamlessly shielding media apps from piracy, preventing CDN leeching, reducing credential theft, and ensuring substantial revenue protection.
- Revenue Protection Cabanas: Reserve a cabana equipped with hammocks and interactive displays to comfortably engage with and learn about award-winning Verimatrix Streamkeeper solutions.
- Cyber Surf Shack: Dive into a surf-themed espresso bar adorned with surfboards and beach cruisers, symbolizing Verimatrix’s agility and adaptability.
Attendees are invited to kick off their shoes and soak up some fun in the sun while staff from Verimatrix highlight the latest in secure streaming, bulletproof cybersecurity, and layered anti-piracy measures. To book at meeting with a Verimatrix security specialist during IBC 2024, email dvanmeter@verimatrix.com or alternatively, book a meeting online.
About Verimatrix
Verimatrix (Euronext Paris: VMX) helps power the modern connected world with security made for people. We protect digital content, applications, and devices with intuitive, people-centered and frictionless security. Leading brands turn to Verimatrix to secure premium movies, live streaming sports, sensitive financial and healthcare data, mission-critical mobile applications, and much more. We enable the trusted connections our customers depend on to deliver compelling content and experiences to millions of consumers around the world. Verimatrix helps partners get to market faster, scale easily, protect valuable revenue streams, and win new business. Visit https://www.verimatrix.com/.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240903597006/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Andersen Consulting tilføjer samarbejdsfirmaet Codezilla7.12.2025 21:19:00 CET | Pressemeddelelse
Andersen Consulting styrker sine kompetencer inden for digital transformation gennem en samarbejdsaftale med Codezilla, et firma med hovedsæde i Rumænien, der udvikler specialtilpasset software. Codezilla specialiserer sig i at udvikle skræddersyede softwareprodukter, der løser forretningsmæssige udfordringer gennem en tværfaglig tilgang, som kombinerer softwareudvikling med dybdegående marketingekspertise. Med over 30 år på markedet fungerer firmaet som implementerings- og digital konsulentressource for reklamebureauer, samtidig med at de arbejder med en bred kundebase, herunder virksomheder inden for sundhedssektoren og medicinsk udstyr. Codezillas interne teams strækker sig over teknik, design og strategi og leverer omnichannel-løsninger til både regionale og globale kunder. "Vi tror på, at fantastisk software er resultatet af solid ingeniørkunst og disciplineret eksekvering," udtaler Sebastian Doroftei, administrerende direktør for Codezilla. "Vores samarbejde med Andersen Consulti
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release
Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom